|Dr. Scott Koenig||CEO, Pres & Director||1.05M||783k||1952|
|Mr. James Karrels||Sr. VP, CFO & Corp. Sec.||613.84k||139.42k||1967|
|Dr. Ezio Bonvini||Sr. VP of Research & Chief Scientific Officer||658.21k||N/A||1954|
|Mr. Eric Blasius Risser||Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer||609.91k||523.31k||1973|
|Dr. Stephen L. Eck||Sr. VP of Clinical Devel. & Chief Medical Officer||577.62k||N/A||1955|
|Anna Krassowska Ph.D.||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Jeffrey Stuart Peters||VP & Gen. Counsel||N/A||N/A||1971|
|Dr. Thomas M. Spitznagel||Sr. VP of BioPharmaceutical Devel. & Manufacturing||N/A||N/A||1967|
|Ms. Lynn Cilinski||VP, Controller & Treasurer||N/A||N/A||1958|
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc.’s ISS governance QualityScore as of 1 July 2021 is 6. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 8; Compensation: 7.